Elli Kaplan
Brain health starts decades before the first symptom
In this interview, Elli Kaplan, CEO and founder of Neurotrack, traces a path from childhood on Native American reservations, where her father practiced pediatrics for the Indian Health Service, through pre-med, the Clinton White House, and the State Department, to the two family diagnoses that convinced her the system for detecting Alzheimer's was broken. She explains how Neurotrack went from one screening test to a platform that helps primary care doctors diagnose and manage the disease, why Medicare now requires cognitive testing at 65, and why Founders Fund backed a company whose science would take a decade. She also makes the case that Alzheimer's is a women's disease shaped by menopause, inflammation, and caregiving, and that exercise, diet, sleep, and hormone therapy are brain health decisions to make decades early.

Elli Kaplan is CEO and founder of Neurotrack, a digital health company whose cognitive care platform helps primary care doctors screen for, diagnose, treat, and manage Alzheimer's disease.
Elli grew up on Native American reservations in Washington and Oklahoma, where her father was a pediatrician with the Indian Health Service, and was pre-med until a professor, Tony Lake, pulled her into the Clinton campaign, the White House, and the State Department. After business school, watching her grandfather and then her grandmother struggle to get an Alzheimer's diagnosis led her to two Emory neuroscientists, and she founded Neurotrack in 2012 with early backing from Peter Thiel's Founders Fund. Its FDA-registered tools are now used by thousands of doctors testing hundreds of thousands of patients.
“There's no amount of wealth that can protect you from it. And if you don't have wealth, it is a really hard disease to manage.”
Elli's core argument is that Alzheimer's is a women's disease, and partly a preventable one, so brain health has to start decades before the first symptom.
"Stop thinking about taking care of yourself as a vanity project," Elli explains. "Think about it through the lens of brain health and taking care of your brain for the long term."
The conversation
In this conversation: Jacqueline Samira (CEO, Howdy) and Elli Kaplan (CEO and Founder, Neurotrack).
I'm Elli Kaplan. I'm the CEO and founder of Neurotrack. Neurotrack is a digital health company bringing to market a cognitive care enablement platform that makes it possible for doctors to better screen for, diagnose, treat, and manage patients with Alzheimer's disease.
It's incredible what you're building. I read a little about your background. Did I read this right? You grew up on a Native American reservation. What was your dad doing?
My dad was a pediatrician with the Indian Health Service. We lived on Indian reservations in Yakima, Washington, with the Yakima tribe, and then in Oklahoma, where, it's blasphemy to say it now, he was an administrator for what they then called the five civilized tribes. Then we moved back to Denver, where I was born, when I was in eighth grade. A difficult time to move.
So you were on reservations from almost the time you were born until eighth grade. What was that experience like as a child?
It really shaped the way I think about the world, and certainly the way I think about health care. It was a much simpler existence, but one with a tremendous sense of culture and value for the earth and all it provided. And a real awareness of disparity, not just socioeconomic, but in access to resources that go beyond niceties: health care resources. I grew up with tribal elders coming to our house late at night with really sick kids. For a long time they were not accepting of Western medicine, but when a child became so sick that their traditional methods weren't working, it was an opportunity of last resort. Seeing how those people loved their children, and these were all children because my dad was a pediatrician, and their way of giving thanks. They would pay my dad in firewood, or sides of beef, or other gifts. We have a lot of moccasins and traditional Native American goods at our house, for the very basic act of helping to care for, and in many cases save, their children's lives.
Was it hard for your dad? Were there things he saw that could have been prevented had he been able to help sooner?
Absolutely. It started with a very understandable mistrust of the white man's medicine. Think about all the wrongs done to Native Americans and the mistrust that existed for so long, and an understandable reluctance to take the recommendations. That showed up in all kinds of ways with preventive medicine, in some cases with vaccines, in others with regular treatment like antibiotics. My dad still talks today about the deep dysfunction around substance abuse, the way it destroyed families and led to other chronic conditions that could have been prevented through better, long-standing care and economic health.
Fast forward. You're in school, you're pre-med, and then you start working for the Clinton administration. How did that come to be?
I really thought I was going to be a doctor. My grandfather was a doctor, my father was a doctor, we had doctors and scientists all over the family. I loved it. I spent every summer working at Children's Hospital in Denver, where he worked. I worked in labs, I was a candy striper, I did it all. I was pre-med through college. But in the middle of my junior year I got interested in politics and international relations, started taking more classes, and had the opportunity to work under one of my professors, Tony Lake, who was Governor Clinton's most senior foreign policy advisor. I started working for him and got pulled into the campaign. It was really fun and exciting, and I decided to delay applying to medical school and go work in D.C. right after Governor Clinton became President Clinton. It felt like a once-in-a-lifetime opportunity, and I still believe that. I started at the White House, then moved to the State Department, working on the most topical foreign policy issues anyone was working on. I kept thinking I'd get back to health care at some point. But once I saw what it meant to play at a national and international level, the idea of working in a clinical environment changed for me. My dad and my grandfather had such a huge impact, but it was one patient at a time, one family at a time. The opportunity to think about populations, and how you have an impact at the population level, was what got me more excited.
I have a lot of friends who are MDs, around 40, and a lot of them are frustrated because they went into med school to have more impact than they feel they can have now. Many are moving into entrepreneurship for that reason. You get into medicine to help people, and then there's so much bureaucracy and red tape. It's an interesting path that let you see it without having to go through it.
I feel that frustration your friends feel, now that I sit where I am and we work with so many providers. They're so frustrated by the bureaucracy of their health system and of health care at large. Our system is so broken that I get it.
Let's talk about what drew you to solving the problem of dementia and Alzheimer's and getting early diagnosis.
It was an accidental path. I eventually went back to graduate school, to business school, and around that time my grandfather, who was also a doctor, started to show signs of memory loss. We lived in Denver, where everyone worked at the university health system. My dad took him to his primary care doctor, and the doctor said, this is just getting older, it's natural, an understandable part of aging, we all lose our memory. It kept getting worse. They asked for a referral into neurology, and it was impossible to get any kind of definitive diagnosis, until they finally said, these are the hallmarks of Alzheimer's disease. It struck me as incredibly infuriating and frustrating and wrong. But I didn't do much about it then. A few years later, my grandmother on my mother's side, same thing: memory loss, a similar response from her provider. That's when I felt it was just not possible that this was happening again to us, and to so many of my friends and other parts of our family, where people were showing symptoms of a disease and hitting walls trying to get answers. As I went down the rabbit hole of understanding how you get a diagnosis, she also got a diagnosis of Alzheimer's. The same thing happened to so many of my friends and their parents. Why was it that the doctors they were trying to see couldn't understand this as a condition, make a diagnosis, and set them on the right referral path? As part of my research, I met two neuroscientists at Emory University doing some of the most cutting-edge research on tools that could help make a diagnosis before it was too late to do something. I talked them into starting a company, and here we are today.
So the researchers joined you to start the company.
Yes, we were all co-founders. They stayed in academia and I ran the business. They were involved in the very early days of taking their technology and commercializing it, and that became our foundational IP. It has since grown dramatically and doesn't look much like it did then. It really came from a view that something was broken in the system, and I was naive enough to think I could at least better understand it and take a stab at it.
Those are the best entrepreneurs. You have to have a level of naivety.
If I could have seen snippets of what was along the way, it would have given me enough fear and doubt that I might not have done it. But I didn't. So here we are.
My husband jokes that the first company is always the easiest to start because you're so naive about the future. You started the company in 2012. Fourteen years later, what does the state of Alzheimer's care and early diagnosis look like? Are you happy with the progress the medical community has made?
It is dramatically different, night and day from when I started Neurotrack. When I started, it was more of a hope and a prayer. There were thousands of what they call disease-modifying drugs in the pipeline, which big pharma and smaller biotechs were trying to develop to slow the progression of, or cure, Alzheimer's. Every single one of those drugs failed. So there was a long period when we were very busy working on our technology and validating it with the view that this was going to happen at some point, we just didn't know when, and we wanted to be ready. What exists today is a universe with two FDA-approved drugs. There's an awareness that preventive measures, similar to what you do to reduce your risk for diabetes or cardiovascular disease, also work for Alzheimer's. And there's a view that early diagnosis is important, which comes from the powers that matter: CMS, the governing body over Medicare and Medicaid, has said cognitive testing must happen at age 65 as part of every annual wellness visit if you want to get reimbursed for it. They've created codes that reimburse for tools like ours. So there are drugs, there are payment mechanisms, and there's recognition that there are things you can do to slow progression. And given that every day 10,000 people turn 65, and the baby boomers are getting older, we have a virtual epidemic on our hands. One in three people at age 85 will have Alzheimer's disease. So we must be doing more, and we're feeling that in the market. We're out selling every day. We work with very large health systems to enable their primary care providers to screen, test, and do a better job of taking care of their patients.
Did I read correctly that Alzheimer's impacts women a lot more than men, and that a lot of the early studies were only done on men? How is research evolving to think through the female side of Alzheimer's?
Of the entire population of people with Alzheimer's disease, two-thirds are women. This is a women's disease. The view is that during menopause, the starvation of the brain of estrogen is really driving that. A lot of newer studies, including a recent retrospective study out of the UK Biobank, show that women who were on estrogen had lower incidences of dementia and Alzheimer's. I think HRT, for women who can take it, is a vital part of protecting your brain, in addition to managing menopause symptoms. There are other reasons too. Alzheimer's is a much more complex disease than we realized. We know there are other causes beyond the well-known hallmarks of amyloid proteins and tau tangles, having to do with inflammation. That's why you see people with diabetes, who have very high levels of inflammation, more prone to it. Lowering your inflammation is a way to reduce your risk. The other piece, as it relates to women, is that women are often caregivers, for children or for parents. During caregiving you spend so much energy and time taking care of others that you stop taking care of yourself. Caregivers have a six times greater risk of developing Alzheimer's. That also contributes to the numbers affecting women.
It makes sense. Caregiving is stressful, that increases your cortisol, cortisol increases inflammation, inflammation increases your chances of Alzheimer's, and you're not taking care of yourself.
Right. And we know exercise is really important for brain health. A largely Mediterranean diet is really important. If you're primarily caregiving, you're probably not making time to exercise, you may not be eating as well, you're under a tremendous amount of stress, and you're probably not sleeping. All of those are risk factors.
How important is early detection? Right now people get tested at 65. What about someone who's 45 or 40? Can you screen earlier?
Changes to the brain that impact your cognitive function and memory begin in your late 20s and early 30s. You don't see significant symptoms until much later. My view is that we should be testing as early as anyone is interested. We work with companies whose patient populations are much younger than 65: companies in the women's health space, and companies focused on people with a strong family history of Alzheimer's who are worried. There we absolutely recommend testing early. Not because you'll see symptoms, but because setting that initial baseline score is so important. If your brain is changing and you have nothing to compare it to, you don't know. If you test at 45, odds are you'll get a normal score. If you're on the earlier side of menopause and experiencing brain fog, that can be reassuring. And it sets the baseline, so when you turn 55 or 65 and you've been testing along the way, you have something to compare to, and proof for your provider that things may be changing.
Your primary customer is the primary care physician? How are they aware you exist, and how many competitors are there? And you took this down the venture route, so I'm curious about that as well.
We sell to primary care providers wherever they exist: very large health systems, organizations that go into the home and do in-home testing, smaller PCP organizations, telehealth companies. They're aware of us because we do a lot of marketing in the places those doctors are, but the thing that matters most is word of mouth. The leadership of these systems talk to each other at medical forums, and dementia is a hot topic, so they hear about us that way. We do have competitors. They tend to approach cognitive testing by going after every area where it exists: ADHD, autism, TBI, all comers. We are very focused on Alzheimer's disease. We screen, and we help a provider make a diagnosis, which is a whole thing unto itself, because these doctors have never done that at the population level. Learning to get comfortable interpreting the results, and even more so having that conversation with the patient and their family, is new. It's behavior change and change management, and we spend a lot of time working with them on it. As providers told us they felt confident making a diagnosis but the waters were murky on what to do next, we developed tools to help them manage those patients: who should get a referral into neurology, who's a good candidate for one of the approved drugs, who should stay in primary care with occupational therapy or speech pathology. As for venture: our tools are FDA registered. We're a medical device company, and we've run many clinical trials validating the tools. That is a hard proposition to bootstrap. It requires real funds. Having spent time in government, with a deep respect for the FDA and the regulatory path, that was the only way to bring something to market.
I read that you went to Peter Thiel at Founders Fund, and what was supposed to be a 30-minute meeting turned into an all-day thing. What do you think they saw in you?
He has long been interested in longevity, not just living a long time but living well for a long time, and had been investing in drugs and tools that could help with that, including some Alzheimer's drugs, because Alzheimer's is a big blocker to living well for a long time. What he realized in that meeting was that a huge reason the drugs were failing was that, because they couldn't diagnose it early, they were testing the drugs on the wrong people. They were too far gone. To have any chance of bringing a drug to market successfully, they needed to test on the right profile of patient, and we could deliver those patients.
Are either of the two approved drugs ones that originally failed and were retried with a better data set?
These were new drugs, focused on the same mechanisms of action. They target amyloid in the brain and reduce it. But they weren't in existence yet, or they were tiny little cells in some lab.
You've been around for 12 years, and venture companies usually have shorter lifespans. Was the pitch, this is going to be a long ride? Normally investors ask, where's the liquidity?
There was an understanding that this was not going to be an overnight success, that science takes time. Bringing a health care product to market in a way that can really scale means, as I always say to our team, you have to make it past the chief medical officer's desk and across the CFO's desk. We could get across the CFO's desk with the reimbursements now in place. It was the CMO's desk that would be challenging without investing the time in longitudinal studies to show the importance of our tool. And there weren't any drugs on the market when he and our early investors invested. These are very smart, savvy people who recognized that drugs also take a long time, so investing in us would be a longer timeline. I feel incredibly fortunate to have investors with very deep pockets who believe, first and foremost, in the opportunity for a huge financial return. Given the size of the population impacted by Alzheimer's, drugs in this space have the potential to be the biggest blockbuster drugs in the history of pharma. GLP-1s might give that statement a run for its money, but short of that, it's still true. And second, they were very aligned with the mission and the view that we're building something that can impact millions of lives.
When you go to your board meetings, what is the key metric you're looking at?
It's changed with time, but now it's revenue and the number of people tested. We're testing hundreds of thousands of people, and thousands of doctors are using our tools. It's about continuing to grow those numbers.
Are you still focused a lot on education and change management with providers?
Absolutely. It's early days. For every provider who is now very comfortable, there are so many more who still aren't, and it takes time. We have an incredible implementation and customer success team, with neurologists, nurse practitioners, primary care docs, and researchers, who go in and sit with the primary care doctor and the medical assistants. The MAs are the first to introduce the test to a patient, and then the doctor explains the results and the next steps. All of that requires change. You can go to the best systems in the country and there are still providers who don't understand this, and it's not their fault. They weren't trained this way. It's new. It's a gift to be able to go in and do that and then have such good outcomes.
What does the future look like for you all?
Our mission has never changed. It has always been about changing the way Alzheimer's disease is diagnosed and treated. As we work with more and more patients, the opportunity is to expand the work we can do. We started as a screening tool, one test, and helped providers learn to use it. We now have multiple tests that do slightly different things to give the provider a deeper, more robust view of what's going on in their patient's brain, very quickly, and then the tools to better manage and care for those patients. Our goal is that the millions of people walking around with the disease but undiagnosed get a diagnosis and a plan for treatment, and the opportunity, as we like to say, to die from something else. It's not a disease you want to live with for a long time.
We have a lot of young founders who watch these interviews. What are two to five things they should be doing now for Alzheimer's prevention?
So many things. It depends on your exact age and your gender. The biggest thing I say to people is: stop thinking about taking care of yourself, exercise and diet, as a vanity project. Think about it through the lens of brain health and taking care of your brain for the long term. When I made that mental shift, it made a big difference in my discipline. When I thought about living a long time with a healthy brain, being able to have grandkids one day and interact with them, it changed everything. If you're young: exercise, a Mediterranean diet, and managing your sleep. For founders, young investment bankers, and management consultants, staying in the office working until midnight every night is not the long way. As you get older, particularly for women, if you're a candidate for hormone replacement therapy, I'd encourage you to think about it strongly. All the things that mattered in your 20s still matter. The other big thing I spend a lot of time thinking about is the stigma that still exists around dementia, Alzheimer's, and brain health. In a younger population that's changing, and we have people like Bryan Johnson and Peter Attia to thank for it. In an older population the stigma still exists, and it makes it hard for people to bring up a family member's decline. If we can all normalize it, talk about getting healthy to take care of your brain at 20, talk about going on HRT at 45 or 50 to take care of your brain, then when you bring it up with your 75-year-old mother, you can say, I think it's important that you get screened, because that's what you can do to take care of your brain now.
That's so important. The work you're doing is incredible. It personally impacted my grandmother, who had Alzheimer's, and my father-in-law, who had dementia. It impacts every single person. There's no amount of wealth that can protect you from it.
There really isn't. There's no amount of wealth that can protect you from it. And if you don't have wealth, it is a really hard disease to manage.
Elli, thank you so much for your time today. I really appreciate it.
It was great to be with you. Thank you.
Be part of the
conversation.
Whether you’re a CEO or founder who wants to be featured or a company interested in sponsoring, there’s a place for you here.